TEMENOS
12.5.2021 08:32:06 CEST | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced that 10,000 business leaders and technologists will come together on 26 - 27 May at TCF Online 2021 , the flagship event in banking. The two-day interactive, online-only event will feature keynotes from PayPal, Barclays and Varo, plus over 50 live and on-demand sessions and 50 industry speakers inspired by a shared mission to make banking better, together. Register for this free to attend event.
Powered by new technologies such as Cloud, AI and SaaS, banks of all sizes can deliver customer experiences that are better, faster and smarter. They can also achieve hyper-efficient cost models to deliver more value to their customers and leverage open ecosystems to enhance and extend their offering. At TCF Online 2021, Temenos will unveil game-changing innovations enabling banks to simplify their operations, innovate and collaborate at speed and digitally transform faster than ever before.
At TCF Online 2021, attendees from over 150 countries will also hear from some of the most influential industry experts in the financial sector, including:
- Ryan Prichard, VP, CTO of Global Credit, PayPal , on the latest innovations in payments, including how PayPal is disrupting the market with its new buy now, pay later product enabled by Temenos technology.
- Ashok Vaswani, CEO of Consumer Banking and Payments, Barclays, on the importance of banks being purpose-led and playing a greater role in the economy and society in a post-pandemic world.
- Colin Walsh, Founder and CEO, Varo , a year on after making history as the first fintech in the U.S. to obtain a national banking license, on making banking more accessible and inclusive for all.
- Jim Marous, co-publisher of The Financial Brand and top 100 influencer, on how banks can humanize their customer experience in a digital world and joining him on the virtual stage, Chris Parker, Co-CEO of Partners Federal Credit Union.
- Eric Purdum, General Manager, DXC on its collaboration with Temenos and accelerating the digital transformation for large tier-1 banks.
- David Hornery, Co-CEO and Co-Founder, Judo, on the future for challenger banks and Judo’s unique approach to the SME market in Australia.
- Barri Maggott, CEO, Curo Fund Services, on the digital transformation journey in funds administration.
- And Max Chuard, CEO of Temenos, on the once-in-a-generation opportunity digital presents for banking, unveiling Temenos’ latest innovations in cloud and AI that will propel the industry forward.
Max Chuard, CEO, Temenos, said: “The urgency for change in banking has never been greater. Consumers and business customers demand and expect fast, frictionless, personalized experiences. Covid-19 has accelerated the trend towards digital banking and new technologies such as Cloud, AI and SaaS make the business case for transformation compelling. Yet while challengers are innovating and launching rapidly on modern technology stacks, legacy systems are still holding banks back. Temenos technology gives all banks the freedom, agility and speed to innovate and adapt to changing customer behavior, business and regulatory change. At TCF Online 2021, our community of thousands will hear about the latest innovations and how together we will make banking better.”
TCF Online brings the key announcements, customer insights and latest software demonstrations from Temenos. To register for this free-to-attend event, visit www.temenos.com/events/tcf-online-2021 .
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005935/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom